[{"id":"023cf6d7-38d4-4089-89bb-ebee230e66e8","acronym":"GLORIOSA","url":"https://clinicaltrials.gov/study/NCT05445778","created_at":"2022-07-06T15:54:42.215Z","updated_at":"2024-07-02T16:34:26.631Z","phase":"Phase 3","brief_title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)","source_id_and_acronym":"NCT05445778 - GLORIOSA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA • MUC16","pipe":" | ","alterations":" FOLR1 expression • MUC16 elevation","tags":["FOLR1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 418","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-06-13"},{"id":"52cbeb93-cca2-4926-a33c-663060dd271d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083844","created_at":"2023-10-16T16:13:46.644Z","updated_at":"2024-07-02T16:35:00.052Z","phase":"Phase 2","brief_title":"Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy","source_id_and_acronym":"NCT06083844","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-05-30"},{"id":"84572fdb-bb5f-45fd-aa5f-f18dedb5e9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05334069","created_at":"2022-04-19T23:53:56.743Z","updated_at":"2024-07-02T16:35:01.625Z","phase":"","brief_title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","source_id_and_acronym":"NCT05334069","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-23"},{"id":"f3bb8c78-51f7-4a14-b736-d95fb6b6695a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05051722","created_at":"2023-01-06T17:59:08.095Z","updated_at":"2024-07-02T16:35:03.376Z","phase":"","brief_title":"Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","source_id_and_acronym":"NCT05051722","lead_sponsor":"Mayo Clinic","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 2640","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-16"},{"id":"4d16483a-46af-471d-a7d7-5aeed864951a","acronym":"FRAGILE","url":"https://clinicaltrials.gov/study/NCT02828618","created_at":"2021-01-18T13:52:09.655Z","updated_at":"2024-07-02T16:35:04.715Z","phase":"","brief_title":"Trial on Radical Upfront Surgery in Advanced Ovarian Cancer","source_id_and_acronym":"NCT02828618 - FRAGILE","lead_sponsor":"AGO Study Group","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 797","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-09"},{"id":"ca2289fb-f2cb-4b25-b323-4166bdc02859","acronym":"","url":"https://clinicaltrials.gov/study/NCT05610735","created_at":"2022-11-09T13:56:41.133Z","updated_at":"2024-07-02T16:35:07.823Z","phase":"Phase 1/2","brief_title":"Combination Therapy for Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05610735","lead_sponsor":"Sham Sunder Kakar","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-04-24"},{"id":"4f33daa7-3ce5-4186-b28f-85f4758b6b4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01116648","created_at":"2021-01-18T04:25:31.641Z","updated_at":"2024-07-02T16:35:10.942Z","phase":"Phase 1/2","brief_title":"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01116648","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation • MUC16 elevation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 04/14/2010","start_date":" 04/14/2010","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 02/13/2025","study_completion_date":" 02/13/2025","last_update_posted":"2024-04-08"},{"id":"3594fa75-445d-45a6-9e2d-074ae9fcbb25","acronym":"","url":"https://clinicaltrials.gov/study/NCT00408590","created_at":"2021-01-18T01:25:56.350Z","updated_at":"2024-07-02T16:35:23.391Z","phase":"Phase 1","brief_title":"Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00408590","lead_sponsor":"Mayo Clinic","biomarkers":" MUC16 • CD4","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 04/19/2004","start_date":" 04/19/2004","primary_txt":" Primary completion: 08/01/2012","primary_completion_date":" 08/01/2012","study_txt":" Completion: 11/07/2017","study_completion_date":" 11/07/2017","last_update_posted":"2024-01-15"},{"id":"6ec53521-6d8c-4c00-8105-0f8b45c02f79","acronym":"","url":"https://clinicaltrials.gov/study/NCT00803569","created_at":"2021-01-18T03:03:05.655Z","updated_at":"2024-07-02T16:35:34.808Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers","source_id_and_acronym":"NCT00803569","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" MUC16 • CTAG1B • CTAG2","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16 • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 11/14/2008","start_date":" 11/14/2008","primary_txt":" Primary completion: 01/24/2011","primary_completion_date":" 01/24/2011","study_txt":" Completion: 01/24/2011","study_completion_date":" 01/24/2011","last_update_posted":"2023-10-04"},{"id":"72fc68c9-215a-40a6-91f6-d9f55c3287fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02020707","created_at":"2021-01-18T09:14:56.657Z","updated_at":"2024-07-02T16:35:35.067Z","phase":"Phase 1","brief_title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","source_id_and_acronym":"NCT02020707","lead_sponsor":"Mayo Clinic","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 02/24/2014","start_date":" 02/24/2014","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-10-02"},{"id":"ad1495a4-53c4-4b07-a3b2-a31c7fdfec87","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014528","created_at":"2023-08-28T14:08:40.926Z","updated_at":"2024-07-02T16:35:38.861Z","phase":"Phase 2","brief_title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","source_id_and_acronym":"NCT06014528","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 09/06/2022","start_date":" 09/06/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-28"},{"id":"bb23c9d2-5b49-4b1a-9605-371d2ef84038","acronym":"","url":"https://clinicaltrials.gov/study/NCT02122185","created_at":"2021-01-18T09:49:52.228Z","updated_at":"2024-07-02T16:35:38.881Z","phase":"Phase 2","brief_title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02122185","lead_sponsor":"University of Chicago","biomarkers":" CEACAM5 • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Suspended","enrollment":" Enrollment 160","initiation":"Initiation: 02/25/2015","start_date":" 02/25/2015","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2023-08-28"},{"id":"833bedae-e936-405e-b52d-8a196f2716bc","acronym":"MATAO","url":"https://clinicaltrials.gov/study/NCT04111978","created_at":"2021-01-18T20:06:18.111Z","updated_at":"2024-07-02T16:35:44.656Z","phase":"Phase 3","brief_title":"MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","source_id_and_acronym":"NCT04111978 - MATAO","lead_sponsor":"Swiss GO Trial Group","biomarkers":" ER • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["ER • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 11/05/2020","start_date":" 11/05/2020","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2023-06-27"},{"id":"995d7ed3-58bc-4c2b-813c-b6a4de641715","acronym":"CRUKD14/001","url":"https://clinicaltrials.gov/study/NCT02546921","created_at":"2022-05-26T00:57:40.094Z","updated_at":"2024-07-02T16:35:46.536Z","phase":"Phase 1","brief_title":"Phase I Study of MOv18 IgE","source_id_and_acronym":"NCT02546921 - CRUKD14/001","lead_sponsor":"Cancer Research UK","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MOv18 IgE"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 02/16/2016","start_date":" 02/16/2016","primary_txt":" Primary completion: 06/22/2021","primary_completion_date":" 06/22/2021","study_txt":" Completion: 07/30/2021","study_completion_date":" 07/30/2021","last_update_posted":"2023-06-05"},{"id":"8da9df0c-215f-464f-b7e6-4299e8415fe2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02759588","created_at":"2021-01-18T13:31:56.704Z","updated_at":"2024-07-02T16:35:58.169Z","phase":"Phase 1b","brief_title":"GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer","source_id_and_acronym":"NCT02759588","lead_sponsor":"Genelux Corporation","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • olvimulogene nanivacirepvec (GL-ONC1)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-01-05"},{"id":"d73b7d49-07e5-44d5-ad25-1092c7461f92","acronym":"ICON9","url":"https://clinicaltrials.gov/study/NCT03278717","created_at":"2021-01-18T16:11:26.978Z","updated_at":"2024-07-02T16:36:03.424Z","phase":"Phase 3","brief_title":"Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients","source_id_and_acronym":"NCT03278717 - ICON9","lead_sponsor":"University College, London","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation • MUC16 elevation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 06/15/2018","start_date":" 06/15/2018","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-09-27"},{"id":"d48c0c5c-3c84-4faf-b5bd-4fc62035039e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03056833","created_at":"2021-01-18T15:03:16.147Z","updated_at":"2024-07-02T16:36:04.347Z","phase":"Phase 1","brief_title":"Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer","source_id_and_acronym":"NCT03056833","lead_sponsor":"Ronald Buckanovich","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/10/2017","start_date":" 06/10/2017","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2022-09-07"},{"id":"fa00b51f-8386-40cd-b19b-3c936a04713e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03794778","created_at":"2021-01-18T18:45:51.723Z","updated_at":"2024-07-02T16:36:07.244Z","phase":"Phase 4","brief_title":"Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer","source_id_and_acronym":"NCT03794778","lead_sponsor":"Women's Hospital School Of Medicine Zhejiang University","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pegylated liposomal doxorubicin • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 396","initiation":"Initiation: 03/19/2019","start_date":" 03/19/2019","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2022-07-18"},{"id":"61b06490-ee64-44ea-a97d-71d3fd122669","acronym":"GYNO-MIR","url":"https://clinicaltrials.gov/study/NCT03776630","created_at":"2021-01-18T18:40:56.818Z","updated_at":"2024-07-02T16:36:07.989Z","phase":"","brief_title":"Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors","source_id_and_acronym":"NCT03776630 - GYNO-MIR","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" MUC16 • MIR200B","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16 • MIR200B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 05/23/2019","start_date":" 05/23/2019","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2022-06-30"},{"id":"2dbed34d-5428-4bc0-85ff-a9b134ca1b93","acronym":"","url":"https://clinicaltrials.gov/study/NCT01296581","created_at":"2021-01-18T05:16:10.054Z","updated_at":"2024-07-02T16:36:16.356Z","phase":"Phase 1","brief_title":"Safety Study of X-82 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01296581","lead_sponsor":"Tyrogenex","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fumena (vorolanib)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2022-02-28"},{"id":"dc057179-f345-46cc-906c-4b748ac8f179","acronym":"","url":"https://clinicaltrials.gov/study/NCT05222204","created_at":"2022-02-05T18:29:14.260Z","updated_at":"2024-07-02T16:36:17.668Z","phase":"Phase 2","brief_title":"DDP ip Combined With AG in PDAC With Peritoneal Metastasis","source_id_and_acronym":"NCT05222204","lead_sponsor":"Fudan University","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 07/02/2023","primary_completion_date":" 07/02/2023","study_txt":" Completion: 07/02/2023","study_completion_date":" 07/02/2023","last_update_posted":"2022-02-03"},{"id":"1cd520b7-d95a-4e1c-8a44-c5ccf4757525","acronym":"","url":"https://clinicaltrials.gov/study/NCT04518501","created_at":"2021-01-18T21:38:58.859Z","updated_at":"2024-07-02T16:36:18.039Z","phase":"Phase 1/2","brief_title":"Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer","source_id_and_acronym":"NCT04518501","lead_sponsor":"Xing Xie","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • MUC16 elevation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • AiRuiYi (fluzoparib) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2022-01-25"},{"id":"4e8e9171-aab2-4b67-a232-655787ef4def","acronym":"QUALOV","url":"https://clinicaltrials.gov/study/NCT04826029","created_at":"2021-04-01T16:52:31.134Z","updated_at":"2024-07-02T16:36:19.615Z","phase":"","brief_title":"Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer","source_id_and_acronym":"NCT04826029 - QUALOV","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 06/22/2021","primary_completion_date":" 06/22/2021","study_txt":" Completion: 06/22/2021","study_completion_date":" 06/22/2021","last_update_posted":"2021-12-10"},{"id":"8d4ab3d0-11ea-458b-b094-6941a461f5b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04217798","created_at":"2021-01-18T20:32:03.574Z","updated_at":"2024-07-02T16:36:25.007Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04217798","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • etoposide oral"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/21/2020","start_date":" 05/21/2020","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2021-09-01"}]